{"id":205850,"date":"2017-07-15T23:22:34","date_gmt":"2017-07-16T03:22:34","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/insider-activity-stryker-corporation-nysesyk-highlight-press\/"},"modified":"2017-07-15T23:22:34","modified_gmt":"2017-07-16T03:22:34","slug":"insider-activity-stryker-corporation-nysesyk-highlight-press","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/insider-activity-stryker-corporation-nysesyk-highlight-press\/","title":{"rendered":"Insider Activity  Stryker Corporation (NYSE:SYK) &#8211; Highlight Press"},"content":{"rendered":"<p><p>Advertisement     <\/p>\n<p>    Here is the rundown on market activity for Stryker Corporation    (NYSE:SYK). Group President, Orthopaedics David Floyd sold    19,305 shares at an average price of $144.56 on Wed the 12th.    Floyd now owns $1,238,590 of stock per an SEC filing yesterday.    David Floyd, Group President, Orthopaedics sold $1,068,031    worth of shares at an average price of $144.70 on Mon the 5th.    That brings the Group President, Orthopaedicss holdings to    $4,033,223 as reported to the SEC.  <\/p>\n<p>    Timothy J. Scannell, Group President sold $1,810,327 worth of    shares at an average price of $135.89 on May 2nd. That brings    Scannells holdings to $15,576,119 as recorded in a recent Form    4 SEC filing.  <\/p>\n<p>    Stryker Corporation (Stryker), launched on February 20, 1946,    is a medical technology company. The Company offers a range of    medical technologies, including orthopedic, medical and    surgical, and neurotechnology and spine products. The    Businesss segments include Orthopaedics; MedSurg;    Neurotechnology and Spine, and Corporate and Other. The    Orthopaedics segment includes reconstructive (hip and knee) and    trauma implant systems and other related products. The    Businesss MedSurg segment consists of instruments, endoscopy,    medical and sustainability products. The Neurotechnology and    Spine segment includes neurovascular products, spinal implant    systems and other related products..  <\/p>\n<p>    These funds have also shifted positions in (SYK). Eqis Capital    Management, Inc. added to its stake by buying 1,575 shares an    increase of 10.3% as of 06\/30\/2017. Eqis Capital Management,    Inc. owns 16,877 shares valued at $2,342,000. The value of the    position overall is up by 16.3%. As of the end of the quarter    Old National Bancorp \/in\/ had sold a total of 241 shares    trimming its holdings by 4.9%. The value of the investment in    (SYK) went from $647,000 to $649,000 increasing 0.3% quarter    over quarter.  <\/p>\n<p>    As of quarter end Lejeune Puetz Investment Counsel LLC had    disposed of 240 shares trimming its position 6.1%. The value of    the investment in SYK decreased from $516,000 to $511,000 a    change of 1.0% quarter to quarter. As of the end of the quarter    Central Trust Co had sold a total of 200 shares trimming its    stake by 5.6%. The value of the investment in Stryker    Corporation decreased from $467,000 to $465,000 a change of    $2,000 since the last quarter.  <\/p>\n<p>    Cantor Fitzgerald added SYK to its research portfolio with a    rating of Neutral. On May 16 analysts at Goldman Sachs    started covering SYK giving it an initial rating of Neutral.  <\/p>\n<p>    On December 15 the stock rating was upgraded to Buy from     in a statement from UBS. On November 1 the company was upgraded    from Underperform to Market Perform in a report from BMO    Capital.  <\/p>\n<p>    Equity analyst SunTrust Robinson Humphrey issued its first    research report on the stock setting a rating of Buy. On June    9, 2016 Guggenheim Securities initiated coverage on SYK with an    initial rating of Buy.  <\/p>\n<p>    The company is so far trading up from yesterdays close of    $143.2. Additionally Stryker Corporation announced a dividend    that will be paid on Monday the 31st of July 2017. The dividend    payment will be $0.425 per share for the quarter or $1.70 on an    annualized basis. This dividend represents a yeild of $1.18    which is the dividend as a percentage of the current share    price. The ex-dividend date will be Wednesday the 28th of June    2017.  <\/p>\n<p>    Shares of the company are trading at $145.40 just above the 50    day moving average which is $140.23 and barely above the 200    day moving average of $130.49. The 50 day moving average went    up by +3.68% and the 200 day average was up $14.91.  <\/p>\n<p>    The company currently has a P\/E ratio of 32.67 and market    capitalization is 54.35B. In the latest earnings report the EPS    was $4.45 and is projected to be $6.43 for the current year    with 373,765,000 shares outstanding. Next quarters EPS is    forecasted to be $1.52 with next years EPS anticipated to be    $7.05.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Original post:<\/p>\n<p><a target=\"_blank\" rel=\"nofollow\" href=\"http:\/\/www.highlightpress.com\/insider-activity-stryker-corporation-nysesyk\/91841\/clarence\" title=\"Insider Activity  Stryker Corporation (NYSE:SYK) - Highlight Press\">Insider Activity  Stryker Corporation (NYSE:SYK) - Highlight Press<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Advertisement Here is the rundown on market activity for Stryker Corporation (NYSE:SYK). Group President, Orthopaedics David Floyd sold 19,305 shares at an average price of $144.56 on Wed the 12th. Floyd now owns $1,238,590 of stock per an SEC filing yesterday.  <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/insider-activity-stryker-corporation-nysesyk-highlight-press\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[187755],"tags":[],"class_list":["post-205850","post","type-post","status-publish","format-standard","hentry","category-neurotechnology"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/205850"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=205850"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/205850\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=205850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=205850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=205850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}